DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
FTRE logo

Fortrea Holdings Inc. Stock Price

NasdaqGS:FTRE Community·US$1.6b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 13 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

FTRE Share Price Performance

US$17.20
7.00 (68.63%)
​
US$20.55
Fair Value
US$17.20
7.00 (68.63%)
16.3% undervalued intrinsic discount
US$20.55
Fair Value
Price US$17.20
AnalystConsensusTarget US$20.55
AnalystHighTarget US$26.00
AnalystLowTarget US$13.00
Tue, 8 Sep 26
Fair ValueUS$20.55
Share Pricen/a

FTRE Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$20.55 16.3% undervalued intrinsic discount

FTRE: Stabilizing Healthcare Trends Will Support Resilience Amid Mixed Market Signals

0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$26 33.8% undervalued intrinsic discount

Global Aging And Digital Trends Will Reshape Clinical Research

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$13 32.3% overvalued intrinsic discount

Regulation And Pricing Will Erode Margins But May Improve Efficiency

1users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
FTRE logo
Fortrea Holdings
16.3% undervalued intrinsic discount
Updated

FTRE: Stabilizing Healthcare Trends Will Support Resilience Amid Mixed Market Signals

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 8 Sep
Read Narrative
FTRE logo
Fortrea Holdings
33.8% undervalued intrinsic discount

Global Aging And Digital Trends Will Reshape Clinical Research

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 25 Aug
Read Narrative
FTRE logo
Fortrea Holdings
32.3% overvalued intrinsic discount

Regulation And Pricing Will Erode Margins But May Improve Efficiency

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 11 Aug
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
FTRE logo

FTRE: Q2 Execution And Early Phase Acquisition Will Drive Future Upside

Fair Value: US$20.55 16.3% undervalued intrinsic discount
8 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
FTRE logo

FTRE: Q2 Beat And Delevering Progress Will Support Turnaround Re Rating

Fair Value: US$26 33.8% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
FTRE logo

FTRE: Q2 Beat And Guidance Raise Will Fail To Sustain Rerating

Fair Value: US$13 32.3% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Undervalued with moderate growth potential.

1 Risk
3 Rewards
View Full Analysis

Fortrea Holdings Inc. Key Details

US$2.7b

Revenue

US$2.2b

Cost of Revenue

US$516.6m

Gross Profit

US$601.8m

Other Expenses

-US$85.2m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.90
19.30%
-3.18%
201.2%
View Full Analysis

About FTRE

Founded
2023
Employees
14000
CEO
Anshul Thakral
WebsiteView website
www.fortrea.com

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Recent FTRE News & Updates

User avatar
Narrative Update • Sep 08

FTRE: Q2 Execution And Early Phase Acquisition Will Drive Future Upside

Fortrea Holdings' analyst fair value estimate has moved from about $17.25 to roughly $20.55, reflecting a series of higher Street price targets in the $20 to $25 range as analysts point to Q2 outperformance, steady bookings, and progress on balance sheet delevering. Analyst Commentary Recent research updates on Fortrea Holdings show a cluster of higher price targets, with analysts reacting to Q2 results, bookings trends, and balance sheet actions.

Recent updates

No updates

Fortrea Holdings Inc. Competitors

PTGX logo

Protagonist Therapeutics

Symbol: NasdaqGM:PTGX
Market cap: US$9.6b
KYMR logo

Kymera Therapeutics

Symbol: NasdaqGM:KYMR
Market cap: US$9.6b
PRAX logo

Praxis Precision Medicines

Symbol: NasdaqGS:PRAX
Market cap: US$9.3b
RGEN logo

Repligen

Symbol: NasdaqGS:RGEN
Market cap: US$9.3b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide